Synonyms: IY-5511 | IY5511 | IY5511HCl | KB-146009 | Supect®
radotinib is an approved drug (South Korea (2012))
Compound class:
Synthetic organic
Comment: This drug is approved only in South Korea, for the treatment of chronic myeloid leukemia (CML), where its trade name is Supect.
It is Example 5 in patent US7501424 [1]. The marketed formulation contains the hydrochloride salt.. View more information in the IUPHAR Pharmacology Education Project: radotinib |
|
No information available. |
Summary of Clinical Use |
A Phase 2I clinical trial (NCT01511289) is currently recruiting participants (Nov 2014). This study will assess the efficacy of radotinib vs. imatinib in newly diagnosed philadelphia chromosome +ve chronic myeloid leukemia patients. Phase 2 trial results are reported in [2]. |
Mechanism Of Action and Pharmacodynamic Effects |
Radotinib's molecular mechanism of action involves inhibition of the tyrosine kinase Bcr-ABL1 fusion [3] and of platelet-derived growth factor receptor (PDGFR) activity. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01511289 | Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | Phase 3 Interventional | Il-Yang Pharm. Co., Ltd. |